feedback

Course Director

Robert Coleman, MD
Robert Coleman, MD

Professor, Department of Gynecologic Oncology and Reproductive Medicine
Executive Director, Cancer Network
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Maha H.A. Hussain
Maha H.A. Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Professor of Medicine, Division of Hematology Oncology, Department of Medicine
Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine
Chicago, Illinois

Mark E. Robson
Mark E. Robson, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Accredited by

Penn State College of Medicine

Activity Description and Educational Objectives

The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms.

Upon completion of this activity, participants will be able to:
  • Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy
  • Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers
  • Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy
  • Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials

Target Audience

The activity will be designed to meet the educational needs of oncologists, nurses, and other allied healthcare oncology professionals involved in the management of patients with cancer who are receiving or who are eligible to receive PARP inhibitor therapy.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 08, 2019 - November 07, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair
Robert Coleman, MD
Professor, Department of Gynecologic Oncology and Reproductive Medicine
Executive Director, Cancer Network
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Coleman, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for: AbbVie Inc.; Aravive; ArQule; AstraZeneca; Cell Medica ; Clovis Oncology; Cordgenics; COR2ED; Eisai Inc.; Geistlich Holding; Genentech, Inc.; Genmab A/S; ImmunoGen Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mersana Therapeutics; MORE Health, Inc.; National Comprehensive Cancer Network; Novocure; OncoMed Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited and TESARO, Inc.
Grant/Research Support from AstraZeneca; Clovis Oncology; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.
Speakers Bureau participant with Banner Health; F. Hoffmann-La Roche Ltd; Medscape; Merck & Co., Inc.; OncLive; Physicians' Education Resource®, LLC.; Research to Practice; Scripps Health; and TargetedOnc.

Faculty
Maha H.A. Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of Medicine
Professor of Medicine, Division of Hematology Oncology, Department of Medicine
Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine
Chicago, Illinois

Maha H.A. Hussain, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer; and Pfizer, Inc.
Other financial interest/relationship Lectures for Astellas Pharma US, Inc.; Genentech, Inc.; and sanofi-aventis U.S. LLC.
Research funding from AstraZeneca; Bayer; Genentech, Inc.; and Pfizer, Inc. (Institution).

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician
Breast Medicine Service and Clinical Genetic Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, New York

Mark E. Robson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; McKesson Corporation; Merck & Co., Inc.; and Pfizer, Inc.
Grant/Research Support from AbbVie Inc; AstraZeneca; Invitae Corporation; Medivation, Inc.; Myriad Genetics, Inc.; and TESARO, Inc.
Honorarium from AstraZeneca.
Other Financial or Material Support from AstraZeneca for travel, accommodations, and expenses.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the CNE accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer(s) have nothing to disclose:

Janice Trainor-Tellier, MSN, RN

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Providership, Credit, and Support


Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6508-20-T.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, Inc., Merck & Co., Inc., and TESARO, A GSK Company.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/CNE Activity

PVI, PeerView Institute for Medical Education, Penn State College of Medicine, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI, Penn State College of Medicine, and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.